---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001830"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:16:12.151932+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arbutus Biopharma Announces Claim Construction Ruling in Patent Lawsuit Against Moderna

## Summary
- Court agreed with Arbutus and Genevant that the claimed mol. % ranges for total lipid ('069 patent) are not limited to 'finished' particles and include standard variation.
- Court held no limitation on mol. % of the claimed cationic lipid with protonatable tertiary amine ('378 patent) as argued by plaintiffs.
- Court construed 'fully encapsulated' mRNA ('651 patent) to mean mRNA wholly contained inside lipid vesicles, distinct from partial encapsulation.
- Arbutus and Genevant seek fair compensation for Moderna's use of LNP technology in its COVID-19 vaccine MRNA-1273 without which the vaccine would not have succeeded.
- Michael J. McElhaugh, Interim CEO, stated the company is pleased with the ruling and remains committed to protecting its intellectual property.

## SEC filing metadata
- accession: 0001171843-24-001830
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324001830/0001171843-24-001830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324001830/f8k_040424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001830
- JSON: https://secwatch.observer/filing/0001171843-24-001830.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.